Nanjing Vcare is located in the biomedical valley of Jiangbei New Area, Nanjing, and builds a 21,000 ㎡ high-end drug R&D center; it has a subordinate manufacturing site located in Hubei Provincial Chemical Park and covers an area of 130 mu, Hubei Tianshu Pharmaceutical Co., Ltd. (referred to as "Tianshu Pharmaceutical"). We have established a high-end drug R & D system and technology platform with both innovation and competitiveness; established a R & D team with rich practical experience and solid professional technology, and learned from internationally advanced management concepts and operation models. We have leading R & D technology platform capacity, perfect quality management system, EHS management system, good delivery records and industry reputation, and have the integrated service capacity of the whole industrial chain from pharmaceutical intermediates to APIs CDMO production and supply, from pharmaceutical CMC to clinical CRO research and registration. By paying attention to the differentiated needs of different customers and flexibly complying with a variety of cooperation modes, we provide global pharmaceutical companies with comprehensive, integrated and end-to-end drug development and manufacturing service enabling platforms, realize comprehensive technical and industrialized support, help customers quickly obtain production approval documents and clinical trial approval documents/licenses, and help customers develop.

At present, we have provided the whole industrial chain and whole life cycle CRO/CDMO services for more than 300 well-known biomedical enterprises and scientific research institutes at home and abroad, assisted customers to obtain more than 20 drug registration approval documents, more than 10 clinical approval documents, more than 50 registration applications are being applied, and more than 3,000 supporting intermediates, impurities and APIs are supplied. Nanjing Vcare makes every effort to ensure the cost controllability and supply chain stability at the R & D and manufacturing stages of customers and help customers' advantages enter the volume-based purchasing and national medical insurance negotiation. At present, customers have won a number of bids for the volume-based purchasing and collection of approved varieties.